U.S. releases policy requiring dual-use biological research reviews amid bird flu debate

"The U.S. government [on Thursday] released a new policy [.pdf] that will require federal agencies to systematically review the potential risks associated with federally funded studies involving 15 'high consequence' pathogens and toxins, including the H5N1 avian influenza virus," Science Insider reports. "The reviews are designed to reduce the risks associated with 'dual use research of concern' (DURC) that could be used for good or evil," the news service writes (Malakoff, 3/29).

According to the Associated Press/ABC News, "The policy lays out steps to help scientists and government agencies determine which projects raise particular concerns about biosecurity and how to ensure that risks from the research are carefully managed from the start" (Neergaard, 3/29). "The launch of the new policy ... comes while a U.S. biosecurity advisory group is meeting to discuss the latest version of two H5N1 transmission papers, one by a group from Erasmus University in the Netherlands and one by a team from the University of Wisconsin, Madison," CIDRAP News notes (Schnirring, 3/29).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients